Angiotensin II: complete guide

Angiotensin II is an octapeptide hormone approved by FDA as Giapreza in 2017 for septic or other distributive shock. This guide covers its structure, mechanism, trial and warnings.

Complete guide5 min read

Key takeaway

FDA first approved synthetic human angiotensin II as Giapreza on December 21, 2017. It is an octapeptide with a molecular weight of 1,046.2 g/mol. In the ATHOS-3 trial, 69.9% of patients met the blood pressure goal at hour 3, versus 23.4% on placebo. Mortality through day 28 was 46% versus 54%, a difference that was not statistically significant.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Giapreza on December 21, 2017.” (this article)
ClassHeart & blood
Body systemsHeart & vessels
Studies cited2 in this article · 2 across 1 article on Angiotensin II
Related productsResearch peptide catalog

Angiotensin II is an eight-amino-acid hormone that tightens blood vessels and raises blood pressure. A synthetic copy is approved for adults in septic or other distributive shock. This guide covers its structure, mechanism, labeled use, pivotal trial, warnings and lab use. Sources were checked on November 17, 2026.

Quick answer: Angiotensin II is a natural peptide hormone and a prescription vasopressor sold as Giapreza. Its label covers raising blood pressure in adults with septic or other distributive shock. It has no boxed warning. The key label warning is a risk of blood clots.

Vitrapep does not sell angiotensin II; this page is a reference summary of published research and regulatory information.

What is angiotensin II?

Angiotensin II is a hormone of the renin-angiotensin-aldosterone system. NCI Thesaurus text in PubChem says it “causes vasoconstriction and an increase in blood pressure.” The body makes it from angiotensin I. Angiotensin converting enzyme removes two amino acids from the end of angiotensin I (PubChem CID 172198). The Giapreza label describes the drug as “synthetic human angiotensin II.” It gives the sequence as aspartyl-arginyl-valyl-tyrosyl-isoleucyl-histidyl-prolyl-phenylalanine, as an acetate salt (Giapreza label, 2021). That is eight amino acids in a straight chain, so it is a short peptide, an octapeptide.

PubChem lists the formula as C50H71N13O12 and the molecular weight as 1,046.2 g/mol (PubChem CID 172198). The label gives the same average weight for the free base. MeSH, quoted in PubChem, calls it “a potent but labile vasoconstrictor.” See our guides to peptide hormones and what peptides are for background.

Drugs@FDA lists the original approval of Giapreza (NDA 209360) on December 21, 2017, to La Jolla Pharma (Drugs@FDA). DailyMed also lists a generic angiotensin II label from Gland Pharma Limited, approved under ANDA 216966, with the same indication (Gland Pharma label, 2022).

Table 1

Angiotensin II: key facts

Fact Detail
Structure type Linear octapeptide (8 amino acids), synthetic copy of the human hormone
Class Vasoconstrictor (vasopressor)
Molecular formula C50H71N13O12
Molecular weight 1,046.2 g/mol
First FDA approval December 21, 2017 (Giapreza, NDA 209360)
Brand names (US) Giapreza (La Jolla Pharmaceutical Company); generic from Gland Pharma

How does angiotensin II work?

The label puts it in one line: “Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release” (Giapreza label, 2021). Vasoconstriction means blood vessels narrow. NCI Thesaurus text in PubChem adds detail. The drug binds type 1 angiotensin receptors on the smooth muscle of blood vessels, which makes the muscle contract. The aldosterone it releases affects how the kidneys handle water and sodium (PubChem CID 172198).

MeSH notes that ACE inhibitors and angiotensin II type 1 receptor blockers are used to block these effects in high blood pressure. Giapreza uses the same hormone for the opposite goal, in shock with dangerously low pressure. Our vasopressin guide covers another peptide hormone that raises blood pressure.

What is angiotensin II approved for?

The Giapreza label states: “GIAPREZA increases blood pressure in adults with septic or other distributive shock.” That is its only labeled use.

What did the key trials show?

ATHOS-3. The pivotal human trial was a randomized, double-blind, placebo-controlled study. It enrolled adults with vasodilatory shock whose blood pressure stayed low despite large amounts of other vasopressors. Of 344 randomized, 321 received study drug and were analyzed: 163 on angiotensin II and 158 on placebo.

The primary end point was a blood pressure response at hour 3. Mean arterial pressure had to rise by at least 10 mm Hg, or reach at least 75 mm Hg, without more background vasopressor. The response rate was 69.9% with angiotensin II and 23.4% with placebo (odds ratio 7.95; P < 0.001). Mortality through day 28 was 46% versus 54% (hazard ratio 0.78; P = 0.12), which was not statistically significant. Serious adverse events occurred in 60.7% and 67.1% of patients (Khanna et al., 2017).

The label reports the same trial, with the end point met by 70% versus 23% of patients. The sponsor’s registry record is NCT02338843, a phase 3 study of 344 participants.

What side effects does the label list?

The Giapreza label has no boxed warning. It states that “the most common adverse reactions reported in greater than 10% of GIAPREZA treated patients were thromboembolic events.” These are blood clots in veins or arteries. Rates in the trial, Giapreza versus placebo, included:

  • Thromboembolic events: 12.9% versus 5.1%
  • Deep vein thrombosis: 4.3% versus 0.0%
  • Thrombocytopenia (low platelets): 9.8% versus 7.0%
  • Tachycardia (fast heart rate): 8.6% versus 5.7%

The single warning section is titled “Risk for Thrombosis.” It calls for clot prevention to be used at the same time (Giapreza label, 2021).

What is angiotensin II’s regulatory status, and how is it used in research?

Angiotensin II is a prescription drug in the United States. Drugs@FDA lists two Giapreza products as prescription and one as discontinued.

Angiotensin II is also a long-standing laboratory tool in animal research. In a 2000 mouse study, apoE-deficient mice given angiotensin II for one month developed worse aortic plaque and abdominal aortic aneurysms. Aneurysms did not form in mice with normal blood lipids, so high cholesterol was needed (Daugherty et al., 2000). These are animal data and do not describe effects in people.

Frequently asked questions about angiotensin II

Is angiotensin II a peptide?

Yes. It is a chain of eight amino acids, an octapeptide, and a natural hormone.

When was angiotensin II approved as a drug?

Drugs@FDA lists the original approval of Giapreza on December 21, 2017.

Did angiotensin II lower deaths in ATHOS-3?

No significant difference was shown. Mortality through day 28 was 46% versus 54%, with P = 0.12.

How is it different from vasopressin?

Both are peptide hormones that can raise blood pressure. Angiotensin II acts on type 1 angiotensin receptors and also increases aldosterone release. See our vasopressin guide for that hormone.

Does angiotensin II have a boxed warning?

No. Its main label warning is a risk of blood clots.

What to know now

  • Structure: linear octapeptide; C50H71N13O12; 1,046.2 g/mol.
  • Approval: Giapreza, December 21, 2017; prescription only.
  • Mechanism: vasoconstriction plus increased aldosterone release.
  • Label use: raising blood pressure in adults with septic or other distributive shock.
  • Evidence: 69.9% versus 23.4% met the hour-3 pressure goal; day-28 mortality difference not significant.
  • Safety: no boxed warning; thromboembolic events are the most common reaction.

What we’re watching

A planned phase 4 trial of angiotensin II for vasoplegia after heart surgery. It is listed as not yet recruiting, with a target of 329 patients (NCT07671365). Further Giapreza label revisions on DailyMed. Related guides: vasopressin, terlipressin and nesiritide.

More for heart & vessels

All 13 compounds for heart & vessels

Sources: La Jolla Pharmaceutical Company 2021, GIAPREZA (angiotensin II) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 209360 (GIAPREZA) . Retrieved November 17, Drugs@FDA: NDA 209360 (GIAPREZA); National Center for Biotechnology Information 2026, PubChem compound summary for CID 172198, angiotensin II; Khanna 2017, The New England Journal of Medicine, 377; La Jolla Pharmaceutical Company 2015; Daugherty 2000, The Journal of Clinical Investigation, 105; Gland Pharma Limited 2022, Angiotensin II prescribing information; Methodist Healthcare System of San Antonio 2026, Angiotensin II for post cardiac surgery vasoplegia (ANGII_V). All 8 citations

Back to the research library

References

  1. La Jolla Pharmaceutical Company. (2021). GIAPREZA (angiotensin II) prescribing information (revised 12/2021). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c265d69a-3efe-4107-9a9e-e6fd3d531c48
  2. U.S. Food and Drug Administration. Drugs@FDA: NDA 209360 (GIAPREZA). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209360
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 172198, angiotensin II. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/172198
  4. Khanna, A., et al. (2017). Angiotensin II for the treatment of vasodilatory shock. The New England Journal of Medicine, 377(5), 419-430. https://doi.org/10.1056/NEJMoa1704154
  5. La Jolla Pharmaceutical Company. (2015). A phase 3 study of LJPC-501 in patients with catecholamine-resistant hypotension (ATHOS-3) (ClinicalTrials.gov ID NCT02338843). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT02338843
  6. Daugherty, A., Manning, M. W., & Cassis, L. A. (2000). Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. The Journal of Clinical Investigation, 105(11), 1605-1612. https://doi.org/10.1172/JCI7818
  7. Gland Pharma Limited. (2022). Angiotensin II prescribing information (revised 9/2022; ANDA 216966). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=727d1102-fc46-46f8-b78e-fd13f0738fe4
  8. Methodist Healthcare System of San Antonio. (2026). Angiotensin II for post cardiac surgery vasoplegia (ANGII_V) (ClinicalTrials.gov ID NCT07671365). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT07671365